Sub-system
Modern biologics plants are built around disposable plastic assemblies rather than fixed stainless steel. It removes cleaning and validation between batches and makes facilities flexible — and it converts a capital asset into a consumable supply chain that can run out.
In one sentence
Single-use systems are pre-sterilised disposable bioprocess components — bags, tubing, connectors and filters — used once and discarded, replacing cleanable stainless steel vessels and pipework.
The argument is compelling. No cleaning validation between batches, no cross-contamination risk, faster changeover between products, lower capital cost, and a facility that can be reconfigured rather than re-plumbed. For multi-product and contract manufacturing sites it is close to the only sensible choice.
The consequence is a permanent dependency. The bag film is a multi-layer polymer qualified for the process, and a change of film or supplier requires evidence that nothing leaches into the product and that the product is unchanged. During the last demand surge this became the visible constraint: facilities existed, and the disposables to run them did not.
Anything that can migrate from plastic into a drug product must be identified and shown to be safe at the levels present. That work is done per film, per process and per product, and it is the reason a manufacturer cannot substitute an apparently identical bag from another supplier when supply tightens.
Film production is specialised, qualification takes months to years, and every user had qualified a specific supplier. Adding capacity meant new extrusion lines and then a queue of customer qualification programmes. It is the same shape as a semiconductor materials shortage, for the same reason: the constraint is qualification, not manufacturing.
Very large scale still favours fixed vessels, because single-use bags have practical size limits and the consumable cost per batch grows with volume. High-volume established products therefore stay in stainless steel, while newer products and contract facilities are predominantly single-use.
2 of these are marked as a chokepoint: a handful of qualified suppliers, a multi-year lead time, or a single geography.
Assemblies are irradiated before use, and that capacity is a separate industrial service.
Safety evidence per material and product is what makes changing supplier a project rather than a purchase.
The safety case for a film is an analytical study of what migrates out of it, which is why qualifying a second supplier is a laboratory programme rather than an order.
Analytical instrumentsMulti-layer film is made on specialised lines, and adding one means plant construction followed by a queue of customer qualification programmes.
Other pages in this map that name Single-use systems as something they cannot do without.
What each company supplies at this step, and — where a public figure exists — its share of this specific market — with what that share measures, the period it covers and who published it. Some rows also show the company’s own reported revenue for the segment covering this step, which is a different thing: it says how much this business matters to that company, not how much of the market it holds. Not a ranking and not a recommendation.
Supplies single-use bags, assemblies and bioprocess consumables.
Supplies single-use bioprocess containers and assemblies.
Supplies bioprocess consumables and equipment through its life sciences segment.
Supplies filtration, chromatography and single-use process components.
Filtration Products segment — 27.3% of Repligen’s reported revenue ($402.8M)FY2025 · company filings · not a market share
Supplies single-use assemblies and filters, and is one of the few vendors qualified across the whole flow path.
Supplies single-use fluid handling and the silicone and polymer tubing the assemblies are built from.
Supplies the pharmaceutical-grade tubing and films most of these assemblies are actually made of.
Supplies high-purity fluid handling components, the same discipline it sells into semiconductor fabs.
Whether film supply is diversified enough to prevent a repeat shortage.
Whether standardised assemblies reduce the qualification burden across suppliers.
Whether waste and sustainability pressure shifts any capacity back to stainless steel.
Each page explains one technology in plain language, states what it depends on, and names companies by what they supply at that step. Company roles are described qualitatively and deliberately carry no market shares, revenue figures or rankings — those change faster than an explainer can, and a stale number is worse than none. Ticker links point at company pages on this site and are provided for reference only.
Nothing here is investment advice, a recommendation, or a forecast. A company named on a page about a technology is not thereby a good investment, and the chokepoints described are structural facts about supply chains rather than predictions about prices. Technology moves; where a page describes something as unresolved or in development, that was true when it was written.
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer